ConductScience.org, home

Paper36733367

Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.

Johanssen T and 8 others. Front Oncol, 2022. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. Papers, record 36733367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36733367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.
PubMed
Journal
Front Oncol
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.79
iCite
Revised in PubMed
2025-05-30
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Johanssen TTimothy
2McVeigh LLaura
3Erridge SSara
4Higgins GGeoffrey
5Straehla JJoelle
6Frame MMargaret
7Aittokallio TTero
8Carragher NONeil O
9Ebner DDaniel

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
28596Cancer Research UKUnited KingdomPubMed

Source PubMed

Download CSV of grants

References212

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133199490Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.Clin Cancer Res2021https://conductscience.org/library/papers/33199490PubMed
217051156Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature2006https://conductscience.org/library/papers/17051156PubMed
325239666Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.Neuro Oncol2015https://conductscience.org/library/papers/25239666PubMed
419519402Hypoxia and radiation therapy: past history, ongoing research, and future promise.Curr Mol Med2009https://conductscience.org/library/papers/19519402PubMed
523042933Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.J Natl Cancer Inst2012https://conductscience.org/library/papers/23042933PubMed
630694423A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.J Neurooncol2019https://conductscience.org/library/papers/30694423PubMed
732012154SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.PLoS Comput Biol2020https://conductscience.org/library/papers/32012154PubMed
829196443Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.Dis Model Mech2018https://conductscience.org/library/papers/29196443PubMed
919720927Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.J Clin Oncol2009https://conductscience.org/library/papers/19720927PubMed
1025762461
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Neuro Oncol2015https://conductscience.org/library/papers/25762461PubMed
1131747009INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.Neuro Oncol2020https://conductscience.org/library/papers/31747009PubMed
1222854781A restricted cell population propagates glioblastoma growth after chemotherapy.Nature2012https://conductscience.org/library/papers/22854781PubMed
1316520474Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial.Ann Intern Med2006https://conductscience.org/library/papers/16520474PubMed
1429300332Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models.Int J Mol Sci2018https://conductscience.org/library/papers/29300332PubMed
1532154928NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.Cancer2020https://conductscience.org/library/papers/32154928PubMed
1616028354Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein.Mol Pharm2004https://conductscience.org/library/papers/16028354PubMed
1729126203A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.Neuro Oncol2018https://conductscience.org/library/papers/29126203PubMed
1832367437Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.J Neurooncol2020https://conductscience.org/library/papers/32367437PubMed
1931882946Deep sequencing and automated histochemistry of human tissue slice cultures improve their usability as preclinical model for cancer research.Sci Rep2019https://conductscience.org/library/papers/31882946PubMed
2032616710Overcoming cancer therapeutic bottleneck by drug repurposing.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32616710PubMed

See all 212 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
41385182VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.Discov Oncol2025https://conductscience.org/library/papers/41385182PubMed
40649933A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen.Int J Mol Sci2025https://conductscience.org/library/papers/40649933PubMed
40430842Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma.Pharmaceutics2025https://conductscience.org/library/papers/40430842PubMed
40430429Structural Activity Relationship Analysis of New Diphenyl PFI-3 Analogues Targeting for the Treatment of Glioblastoma.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40430429PubMed
38139302Frentizole, a Nontoxic Immunosuppressive Drug, and Its Analogs Display Antitumor Activity via Tubulin Inhibition.Int J Mol Sci2023https://conductscience.org/library/papers/38139302PubMed
37485377Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells.iScience2023https://conductscience.org/library/papers/37485377PubMed

Download CSV of cited by

Genes39

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALOX5240PubTator's text mininghttps://conductscience.org/library/genes/240NCBI Gene
ASPM259266PubTator's text mininghttps://conductscience.org/library/genes/259266NCBI Gene
CASP1834PubTator's text mininghttps://conductscience.org/library/genes/834NCBI Gene
CTSB1508PubTator's text mininghttps://conductscience.org/library/genes/1508NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
E2F61876PubTator's text mininghttps://conductscience.org/library/genes/1876NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EPAS12034PubTator's text mininghttps://conductscience.org/library/genes/2034NCBI Gene
FOXM12305PubTator's text mininghttps://conductscience.org/library/genes/2305NCBI Gene
GGH8836PubTator's text mininghttps://conductscience.org/library/genes/8836NCBI Gene
HIF1A3091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
HSP90AA13320PubTator's text mininghttps://conductscience.org/library/genes/3320NCBI Gene
IDH13417PubTator's text mininghttps://conductscience.org/library/genes/3417NCBI Gene
IL183606PubTator's text mininghttps://conductscience.org/library/genes/3606NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAP4K49448PubTator's text mininghttps://conductscience.org/library/genes/9448NCBI Gene
MAPK45596PubTator's text mininghttps://conductscience.org/library/genes/5596NCBI Gene

See all 39 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36733367

GET https://conductscience.org/api/papers/v1/36733367/references?page=2